LGALS9 and neoplasm: In addition, an ongoing phase1/2 trial in patients with metastasized solid tumors explores the safety, pharmacokinetics, and anti-tumor activity of a galectin-9-targeting antibody, either as monotherapy or combined with chemotherapy or anti-PD-1 treatment (NCT04666688).